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utations in the gene of the peripheral myelin
protein zero (P0) give rise to the peripheral neu-
ropathies Charcot-Marie-Tooth type 1B disease
(CMT1B), Déjérine-Sottas syndrome, and congenital hypo-
myelinating neuropathy. To investigate the pathomechanisms
of a speciﬁc point mutation in the 
 
P0
 
 gene, we generated
two independent transgenic mouse lines expressing the
pathogenic CMT1B missense mutation Ile106Leu (P0sub)
under the control of the P0 promoter on a wild-type
background. Both P0sub-transgenic mouse lines showed
M
 
shivering and ultrastructural abnormalities including retarded
myelination, onion bulb formation, and dysmyelination seen
as aberrantly folded myelin sheaths and tomacula in all
nerve ﬁbers. Functionally, the mutation leads to dispersed
compound muscle action potentials and severely reduced
conduction velocities. Our observations support the view
that the Ile106Leu mutation acts by a dominant-negative
gain of function and that the P0sub-transgenic mouse
represents an animal model for a severe, tomaculous form
of CMT1B.
 
Introduction
 
The hereditary motor and sensory neuropathies are a clinically
and genetically heterogeneous group of diseases of the pe-
ripheral nervous system of humans (Young and Suter, 2001,
2003). Among the different forms of these diseases is the
Charcot-Marie-Tooth (CMT) type 1 neuropathy (Kamholz
et al., 2000). CMT1 is characterized by distal muscle
weakness and atrophy, reduced nerve conduction velocities,
and de- and remyelination with onion bulb formation as
observed in sural nerve biopsies (Dyck et al., 1993). Among
the main forms of CMT1, CMT1B is caused by mutations
in the major peripheral myelin protein zero (P0; Hayasaka et
al., 1993a,c; Kulkens et al., 1993; Shy et al., 2002). Mutations
in 
 
P0
 
 also give rise to severe disorders such as Déjérine-Sottas
syndrome (DSS) and congenital hypomyelinating neuropathy
(Hayasaka et al., 1993b; for reviews see Warner et al., 1996;
Martini et al., 1998; Kamholz et al., 2000; Bennett and
Chance, 2001; Shy et al., 2002).
P0 is a transmembrane recognition molecule that belongs
to the Ig superfamily. It acts as a homophilic adhesion
molecule involved in the formation and maintenance of the
intraperiod and major dense lines that are instrumental in
the compaction of myelin lamellae (Schneider-Schaulies et
al., 1990; Martini, 1994; Martini et al., 1995a). Crystallo-
graphic analysis supports the notion that the extracellular
domain of the molecule is involved in interdigitation of
P0 tetramers on opposing myelin lamellae (Shapiro et al.,
1996; Inoue et al., 1999). Experiments on the P0-deficient
mouse indicate a role for P0 not only in myelin formation,
but also in maintenance of myelin integrity (Martini and
Schachner, 1997).
P0 null mutant mice have been considered as a model
of patients with DSS that are homozygous for functional
null mutations (Giese et al., 1992; Martini et al., 1995b;
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Warner et al., 1996). The heterozygous P0 null mutant
mouse represents a late onset, milder neuropathy, and has
been considered as a model for CMT1B patients carrying a
loss of function mutation in one allele (Martini et al.,
1995b; Martini, 1999). The majority of human 
 
P0
 
 muta-
tions is heterozygous and causes a more severe phenotype
than that of heterozygous P0-deficient mice. It has been
suggested that these mutations act through gain of func-
tion (Hayasaka et al., 1993b; Kirschner and Saavedra,
1994). The possibility that some mutations may act through
gain of function and others through loss of function could
explain, at least to some extent, the findings that patients
carrying mutations in the 
 
P0
 
 gene are either affected by the
mild form of CMT1B or more severe forms of the disease
(Martini et al., 1995b).
To develop a mouse model of a severe and early onset
form of CMT1B, we have generated a transgenic mouse line
with a substitution of isoleucine at residue 106 to leucine
(P0sub; Gabreëls-Festen et al., 1996). This mutation in the
human is characterized by the occurrence of many folded
myelin profiles, termed tomacula, appearing as focally thick-
ened myelin passing into thinner myelin sheaths within the
same internode. Fibers outside tomacula are frequently de-
void of myelin or are thinly (re)myelinated. Onion bulbs are
composed of thin Schwann cell layers and contain many
double basement membranes. Uncompacted myelin is en-
countered only in few fibers. Here, we report that transgenic
mice expressing this point mutation in conjunction with the
two endogenous wild-type P0 alleles show a similar pheno-
type, including severe muscle weakness, hypomyelination,
tomacula formation, and low conduction velocities, as well
as retarded and arrested myelin development.
The combined observations support the view that the
Ile106Leu mutation acts by dominant-negative gain of func-
tion and that the P0sub-transgenic mice represent the first
authentic model for the severe and early onset form of
tomaculous CMT1B in humans.
 
Results
 
Transgenic mice expressing the P0 substitution 
mutation show motor abnormalities
 
An A
 
→
 
T nucleotide exchange was introduced into exon 3
of the 
 
P0
 
 gene to express the pathogenic P0 missense muta-
tion Ile106Leu (Gabreëls-Festen et al., 1996) under the con-
trol of the P0 promoter in addition to endogenous P0 ex-
pression. The expression construct (termed P0sub; Fig. 1)
included 6 kb of 5
 
 
 
 flanking sequence, all exons and introns,
and the natural polyadenylation signal (Feltri et al., 1999).
The P0 promoter was previously shown to regulate the ex-
pression of lacZ in parallel with the endogenous P0 pro-
moter during postnatal development and after Wallerian de-
generation (Feltri et al., 1999), and to produce structurally
normal myelin when P0 was expressed in P0
 
 
 
/
 
 
 
 mice (Wra-
betz et al., 2000).
We produced two founder P0sub mouse lines (P0sub1
and P0sub3) which transmitted the transgene to their off-
spring. The transgenic mice of both lines shivered dramat-
ically and showed different signs of muscle weakness pro-
nounced from the fourth week onwards. For example,
when placed on a pole they were either not able to grab
the pole with their hindlimbs or slipped down if they tried
to grab the pole. In addition, the transgenic mice fre-
quently dragged their paws while walking and clenched
their paws while hanging at their tails. The transgenic
males were not able to breed, most likely due to impaired
motor abilities.
Figure 1. Design of the P0sub-transgenic construct. Shown is the 
localization of the substitution mutation within the P0 transgene 
and the changes (underlined) in comparison to the wild-type (wt) 
sequence at the level of nucleotides (in lowercase letters) or amino 
acids (in capital letters). The position of important restriction sites 
and their corresponding enzymes are indicated above the construct. 
Black boxes, exons; gray box, 3  untranslated region of exon 6; pA, 
polyadenylation signal.
Figure 2. RT-PCR analysis demonstrates overexpression of the 
transgene in P0sub mice. (A) Total RNA prepared from sciatic nerve 
was reverse transcribed; the product was amplified by PCR using a 
primer pair that recognized identically both endogenous (endo) and 
transgenic (tg) P0 cDNAs. The tg cDNA could be distinguished from 
the endo cDNA by DdeI digestion, yielding a tg-specific fragment 
of 228 nt and an endo-specific fragment of 245 nt. (B) Reverse-
transcribed products from sciatic nerve total RNA of 6-wk-old 
transgenic (tg) P0sub1 and P0sub3 mice were analyzed for the relative 
proportions of transgenic and endogenous P0 mRNA. In both lines, 
an overexpression of transgenic mRNA was observed. Note that for 
cDNA from wild-type (wt) littermates used as a control, only the 
245-nt band was detected, confirming the specificity of the 228-nt 
band for transgenic P0 cDNA. Aliquots of different PCR cycle 
numbers (22, 24, and 26) were analyzed in order to ensure that 
only the logarithmic phase of PCR was considered for quantification. 
The P0sub3-transgenic samples and the corresponding wild-type 
control were grouped from different parts of the same gel for reasons 
of space (film exposure was identical). 
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The transgenic P0 mRNA is overexpressed compared 
with the endogenous P0 transcripts in P0sub mice
 
To determine the ratio between transgenic and endogenous
P0 message in P0sub mice, we used an RT-PCR assay based
on a method described by Feltri et al. (1999), exploiting a
DdeI site present in the sub transgene, but not in the endog-
enous 
 
P0
 
 (Fig. 2 A). After DdeI digestion of RT-PCR prod-
ucts from sciatic nerves, a 228-nt band, corresponding to the
transgenic message, was observed in all samples from trans-
genic mice, and appeared more intense than a 245-nt band
representing the endogenous P0 mRNA (Fig. 2 B). The
228-nt band was specific, as omission of reverse transcrip-
tion product did not produce any bands (unpublished data),
and DdeI digestion of RT-PCR product from wild-type ani-
mals only yielded the 245-nt band (Fig. 2 B). Densitometry
revealed that in P0sub1 and P0sub3 mice, the transgenic P0
mRNA is approximately sixfold overexpressed relative to the
endogenous P0 mRNA (Table I).
 
P0 protein is not overexpressed in myelin of P0sub mice
 
The content of P0 within peripheral nerves was estimated by
immunoblot analysis of total nerve homogenates (Fig. 3, A
and B). The P0-immunoreactive bands of transgenic mice in
the founder lines P0sub1 (Fig. 3 A) and P0sub3 (Fig. 3 B)
were decreased by 
 
 
 
10-fold when compared with equal pro-
tein amounts of wild-type mice (Table II). This finding
might reflect the strong hypomyelination observed in pe-
ripheral nerves (see below), but does not relate to the
amount of P0 protein incorporated into myelin.
To investigate if the abnormal phenotype of P0sub mice is
the result of an overexpression of P0 protein in myelin, we
characterized the myelin fraction of peripheral nerve ho-
mogenates by immunoblot analysis (Fig. 3, C and D). We
obtained different results for the two founder lines: although
the amount of P0 in the myelin fraction of P0sub1-trans-
genic mice (Fig. 3 C) was reduced by approximately fivefold
compared with wild-type mice, the P0sub3-transgenic mice
(Fig. 3 D) showed a P0 content in the range of that seen in
wild-type mice (Table II). These data exclude the possibility
that an over- or underexpression of P0 protein in peripheral
 
Table I. 
 
P0 transgenic mRNA is overexpressed relative to 
endogenous mRNA in P0sub mice
Mouse line P0sub1 P0sub3
 
Fold overexpression
of transgenic mRNA
6.0 
 
 
 
 0.3 6.1 
 
 
 
 0.7
Mice were 42 d old; 
 
n
 
 
 
 
 
 4 for both lines; values are given as mean 
 
 
 
 SD.
Figure 3. P0 immunoblot analysis of total and myelin fraction 
of peripheral nerve homogenates of wild-type and P0sub mice. 
(A and B) In immunoblots of total nerve homogenates, the intensities 
of the P0-immunoreactive bands of the P0sub1- and P0sub3-trans-
genic mice are dramatically reduced ( 10 times) compared with 
wild-type mice. This accounts for the low content of myelin in the 
sciatic nerves of the transgenic animals. (C and D) Although the 
amount of P0 protein within peripheral myelin of P0sub3-transgenic 
mice is comparable to that of wild-type mice (D), the P0 content is 
significantly reduced in myelin isolated from transgenic mice of 
P0sub1 (C). Different amounts of protein were applied (for A and B): 
lanes 1 and 7, 0.1  g; lanes 2 and 8, 0.2  g; lanes 3 and 9, 0.5  g; 
lanes 4 and 10, 1  g; lanes 5 and 11, 2  g; lanes 6 and 12, 5  g; 
and (for C and D): lanes 1 and 6, 0.01  g; lanes 2 and 7, 0.05
 g; lanes 3 and 8, 0.1  g; lanes 4 and 9, 0.25  g; lanes 5 and 10,
0.5  g. P0 protein was detected with polyclonal P0 (A and B) or 
monoclonal P07 (C and D) antibody.
 
Table II. 
 
P0 protein expression in P0sub-transgenic mice relative to wild-type littermates
Mouse line P0sub1 P0sub3
Wild-type mice Transgenic mice Wild-type mice Transgenic mice
 
Expression of P0 protein in
sciatic nerve homogenate
 
a
 
1.00 
 
 
 
 0.29 0.12 
 
 
 
 0.05 1.00 
 
 
 
 0.10 0.09 
 
 
 
 0.04
Expression of P0 protein in
myelin fraction
 
a
 
1.00 
 
 
 
 0.48 0.21 
 
 
 
 0.03 1.00 
 
 
 
 0.65 1.04 
 
 
 
 0.70
 
a
 
Average P0 protein level in wild-type animals was set to 1; mice were 56 d old; 
 
n
 
 = 3 for both lines; values are given as mean 
 
 
 
 SD. 
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myelin may cause the abnormal phenotype of P0sub-trans-
genic mice.
 
Light microscopic and ultrastructural abnormalities in the 
peripheral nervous system of the P0sub-transgenic mice
 
adult stage. 
 
To obtain quantitative histopathological data,
we investigated the two major branches of the femoral nerve
of P0sub1 and P0sub3 mice, comprising the motor quadri-
ceps and cutaneous saphenous nerve, by EM. The quadri-
ceps nerve contains 
 
 
 
550 myelinated axons that are pre-
dominantly of larger caliber, whereas the saphenous branch
comprises 
 
 
 
650 myelinated axons of predominantly smaller
caliber (Lindberg et al., 1999). In addition, and as opposed
to the quadriceps nerves, unmyelinated nerve fibers are
abundant in the saphenous branch.
In 6-mo-old wild-type mice, the two major branches of
the femoral nerves were completely myelinated. However, in
both lines of the transgenic mice, myelination was severely
impaired in both branches of the femoral nerve, but axon
numbers were not significantly reduced in these nerves (568 
 
 
 
14.8 in the mutants and 554 
 
 
 
 16.7 in wild types; P 
 
 
 
0.3). The typical pathological profiles in the cross-sectioned
femoral nerves were abnormally folded myelin profiles and
myelin thickenings of normal compaction (
 
 
 
12 and 10% of
all axonal profiles of lines P0sub1 and P0sub3, respectively;
Fig. 4 and Fig. 5). In the following, we designate these ab-
normalities as tomacula. In addition, abnormally thinly my-
elinated profiles (
 
 
 
9 and 10% in P0sub1 and P0sub3, re-
spectively) or axons completely devoid of myelin (43 and
48% in P0sub1 and P0sub3, respectively) were abundant
(Fig. 4 and Fig. 5 A). Furthermore, supernumerary Schwann
cells in the form of onion bulbs were frequently seen (Fig. 5
A). These abnormal features were also seen in sciatic nerves
(Fig. 5 C) and spinal roots (Fig. 5 D), and are highly remi-
niscent of those described for sural nerve biopsies from a
CMT1B patient carrying the same P0 mutation as the trans-
genic mice (Gabreëls-Festen et al., 1996).
As a next step, we investigated single-fiber preparations
from quadriceps nerves of both wild-type and mutant mice.
In wild-type mice, myelin sheaths were regularly shaped
with nodes of Ranvier forming the borders of apposing
sheaths (Fig. 5 E). By contrast, in both transgenic lines, all
fibers prepared were of abnormal appearance (50 fibers from
2 different mutant mice of each line). Each of the fibers
showed tomacular swellings that were either internodal or at
a paranodal position (Fig. 5 F). In addition, and in support
of the electron microscopic analyses, the aspects not asso-
ciated with tomacula showed much thinner myelinated
profiles than those of wild-type mice, or lacked myelin
completely.
Electrophysiological investigations of adult mice of the
P0sub1 line revealed a robust reduction of amplitudes of
compound muscle action potentials of plantar muscles from
12.8 mV (
 
 
 
2.9 mV) in wild-type mice to 1.1 mV (
 
 
 
0.19
mV) in the mutants. Mean nerve conduction velocity was
reduced from 40.2 m/s (
 
 
 
 2.9 m/s) to 2.0 m/s (
 
 
 
 0.3 m/s,
P 
 
 
 
 0.001) with dispersed response. F-wave latency could
not be recorded at this age (Fig. 6), but in 2-mo-old mu-
tants, a dramatically prolonged F-wave (4.7 
 
 
 
 0.4 ms in
wild-type mice vs. 48 
 
 
 
 5.5 ms in the mutants, P 
 
 
 
 0.001)
could be recorded. Similar values were obtained from line
P0sub3 (unpublished data).
 
Developmental stages. 
 
To investigate whether the severe
myelinopathy of the transgenic mice developed at onset of
myelination or was the result of myelin degeneration, we in-
vestigated the quadriceps branch of the femoral nerve of
wild-type and transgenic mice at 4 and 10 d, and at 1 and 4
mo of age.
In 4-d-old wild-type mice, 
 
 
 
50% of the fibers of the
quadriceps nerve showed myelin sheaths that were all of thin
appearance (Fig. 4). In 10-d-old mice, almost all fibers were
myelinated, including myelin sheaths of normal and low
thickness (Fig. 4). During the following stages, all myelin-
ated fibers of the wild-type mice increased in diameter and
achieved their final size at 4 mo.
In both mutant lines, there was no detectable myelin at
postnatal d 4 and only very few fibers showed myelinated as-
pects at postnatal d 10 (Fig. 4). At 1 mo after birth, three
groups of myelinated fibers were detectable comprising visu-
ally normal myelin, myelin tomacula, and abnormally thin
myelin (Fig. 4). These myelin-like sheaths constantly in-
creased in number up to 6 mo after birth, the oldest stage in-
vestigated. In spite of this increase, 
 
 
 
43 and 48% of the
nerve fibers of P0sub1 and P0sub3, respectively, remained
Figure 4. P0sub causes impaired myelin development, myelin 
arrest, and tomaculous abnormalities. Left side: EM-based morpho-
metric analysis of femoral quadriceps nerves of developing (4 d, 10 d, 
and 1 mo) and adult (4 and 6 mo) P0sub1 and P0 wt mice. The 
numbers of the distinct morphological profiles (e.g., the “number of 
axons with myelin of normal thickness”) are given as percentage 
values of the total axon number of the femoral nerve ( 550). “n” 
indicates the number of mice used for a respective age. Right side: 
representative semi-thin sections of femoral quadriceps nerves of 
6-mo-old P0sub1 mutants and wt mice, reflecting the strongly 
impaired myelin formation in the mutants. Arrows indicate tomacular 
profiles in the mutant, asterisks nonmyelinated axons of larger caliber. 
More pathological details are given in Fig. 5. Bar in the bottom mi-
crograph (for both micrographs) is 20  m. 
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unmyelinated (see above and Fig. 4). It is of note that the
developing Schwann cells of the mutant showed an abnor-
mal cytological appearance in that many of them contained
abundant cytoplasmic myelin ovoids (unpublished data).
 
Discussion
 
The phenotype of P0sub mutants is caused by a P0 
missense mutation
 
To develop an authentic mouse model for one severe and
early onset form of CMT1B, we have generated two inde-
pendent transgenic mouse lines expressing the pathogenic
CMT1B missense mutation Ile106Leu (Gabreëls-Festen et
al., 1996) under the control of the P0 promoter (Feltri et al.,
1999) on a wild-type genetic background. Both P0sub
mouse lines showed severe impairment of their motor abili-
ties with remarkable muscle weakness. Morphological inves-
tigation of peripheral nerves of these mice revealed a severe
myelinopathy that includes features of early onset dysmy-
elination, such as prominent hypomyelination and tomacula
formation in all nerve fibers. These characteristics are very
similar to the pathological phenotype of the severely affected
Figure 5. P0sub causes a tomaculous neuropathy with impaired myelin formation in peripheral nerves. Electron micrographs of femoral 
quadriceps nerves (A and B), sciatic nerves (C), and dorsal spinal roots (D) of adult P0sub1 mutants and single-fiber preparations from sciatic 
nerves of adult wild-type (E) and P0sub1 mutants (F). (A) Low power overview of a femoral quadriceps nerve of a P0sub1 mutant. Note 
tomacula (arrows), onion bulbs (arrowheads), and nonmyelinated axons of large caliber (asterisks) as typical pathological features. (B) High 
power EM of a tomaculum in the femoral quadriceps nerve of a P0sub1 mutant. Note folded and unusually thick myelin that displays 
normal compaction. Ax, axon. (C and D) Low power overviews of a sciatic nerve and a dorsal spinal root of a P0sub1 mutant. Note similar 
neuropathic hallmarks as seen in the femoral nerve. Arrows, tomacula; arrowheads, onion bulbs; asterisks, nonmyelinated large caliber 
axons. (E and F) Single-fiber preparations from wild-type (E) and P0sub1 mutant (F) mice. Note frequent tomacula in the mutants and absence 
of tomacula in the wild types. Arrows indicate nodes of Ranvier. Bars: 5  m (A, C, and D), 1  m (B), and 40  m (F, for E and F). 
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CMT1B patient that has initially been described as suffering
from a congenital demyelinating motor and sensory neurop-
athy (Gabreëls-Festen et al., 1990). Later on, when genetic
analyses were available, this patient was identified to carry an
Ile106Leu substitution mutation in the 
 
P0
 
 gene and was
classified as a CMT1B patient (Gabreëls-Festen et al.,
1996). Electrophysiologically, we found strongly reduced
nerve conduction velocities of only 2 m/s that again reflect
the severe phenotype of the aforementioned patient display-
ing conduction velocities of 7 m/s. In our P0sub mutants,
we observed a strong retardation and partial arrest of the
myelination process during development, which is again in
line with the pathological features of the aforementioned pa-
tient, whose pathological abnormalities have been identified
at early childhood (Gabreëls-Festen et al., 1990, 1996).
We investigated the relative expression of transgenic and
endogenous P0 message in P0sub mice and found that in
P0sub1 and P0sub3 mice, the transgenic P0 mRNA is ap-
proximately sixfold overexpressed relative to the endogenous
P0 mRNA. It is of note that a comparably high overexpres-
sion of the full-length 
 
P0
 
 transgene (approximately by factor
7 in the mutant Tg80.2) containing the 
 
P0
 
 wild-type gene
leads to severe dysmyelination characterized by impaired
axon sorting and arrest of myelin formation at the promy-
elin stage (Wrabetz et al., 2000; Yin et al., 2000). The dys-
myelinating neuropathy in our model is strikingly different
from that observed in the P0-overexpressing Tg80.2 mu-
tants because impaired sorting and persistence of axon bun-
dles of larger calibers were never observed in our P0sub
mice. In addition, P0 protein is not overexpressed in the my-
elin fraction of adult P0sub mutants, whereas P0 protein was
overexpressed in the adult Tg80.2 mutant by a factor of
 
 
 
1.4 as evaluated by quantitative immuno-EM of the few
myelin structures that were detectable in the transgenic over-
expressors (Yin et al., 2000). Most importantly, both the
P0sub1 and the P0sub3 lines developed tomaculous myelin
structures in all peripheral nerve fibers, although the P0 pro-
tein levels differed by a factor of 
 
 
 
5 in the myelin fractions
from the two sublines and never exceeded those of wild-type
littermates. Occurrence of tomacula cannot be explained by
the overexpression of P0 transcripts because tomacula have
never been observed in transgenic mice overexpressing P0
(Wrabetz et al., 2000; Yin et al., 2000). Another transgenic
mutant developed in our laboratory in parallel with P0sub1
and P0sub3, which expresses a human P0 mutation causing
a DSS, does not produce myelin tomacula either, but is
characterized by reduced myelin thickness (unpublished
data). Therefore, we conclude that tomacula formation and
most probably also the observed arrested myelination is a
unique feature of P0sub1 and P0sub3 mice reflecting the ef-
fects of the substitution mutation.
 
The P0sub mutation is consistent with a
dominant-negative gain of function
 
The most common features of CMT1B are hypo- and de-
myelination, combined with onion bulb formation. How-
ever, based on additional neuropathological features, two
divergent forms of the disorder have been described (Ga-
breëls-Festen et al., 1996). The first form is character-
ized by the frequent occurrence of uncompacted myelin
(
 
 
 
20–70% of myelinated fibers), whereas tomacula are al-
most absent (
 
 
 
1%). These features are most similar to the
phenotype of heterozygous P0-deficient mice (Martini et
al., 1995b), which thus express the characteristic features of
these forms of CMT1B. The pathology of the other type
of CMT1B, including the phenotype associated with the
Ile106Leu substitution, is dominated by the abundant
occurrence of tomacula and a lack of uncompacted my-
elin (
 
 
 
1%; Gabreëls-Festen et al., 1996). To date, to-
maculous forms of CMT1B are described for six fur-
ther point mutations: Ile33Phe, Ser49Leu, Lys67Glu,
Asn93Ser, Lys101Arg, and Asn102Lys (Thomas et al.,
1994; Gabreëls-Festen et al., 1996; Tachi et al., 1997; Nak-
agawa et al., 1999; Sindou et al., 1999; Fabrizi et al., 2000),
of which the molecular pathology is unknown and which
remain to be investigated in transgenic mouse models. We
have shown that, in the presence of two P0 wild-type al-
leles, the P0sub-transgenic mice develop the same abnormal
features and pathological characteristics as the human mu-
tation Ile106Leu, which is a conservative amino acid substi-
tution. It is worth mentioning in this context that this ab-
normal phenotype is not caused by a functional ablation of
the mutant P0 allele in the sense that it causes a null muta-
tion because heterozygous P0-deficient mice show normal
development and maintenance of myelin until 4 mo of age,
after which they display decompaction and degeneration of
myelin. P0sub-transgenic mice, by contrast, show a severe
and early onset dysmyelination, accompanied by the forma-
tion of tomacula in the absence of myelin decompaction.
Thus, our results strongly suggest that the pathological phe-
notype of tomacula in P0sub-transgenic mice is the result of
a dominant-negative gain of function effect of P0 protein
that can impair the normal function of P0.
Figure 6. Representative traces of nerve conduction experiments 
with distal stimulation of the tibial nerve of 6-mo-old mice at the 
ankle and needle electrode recording from intrinsic foot muscles. 
(A) Normal amplitude of 11.0 mV and normal latency of 1.1 ms 
in the wild-type animal; normal F-wave response is depicted by 
arrowhead. (B) In the P0sub mutant (P0sub1), there is a disperse, 
polyphasic potential of only 1.0 mV; latency is prolonged to 5.2 ms 
(note different scales of time and amplitude axis). Arrows (in A and B) 
show stimulus artifact. 
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With regard to the developmental aspect of our work, we
cannot rule out that the severe phenotype of the two P0sub-
transgenic mouse lines is partially due to an overexpression
of the mutant protein during development, possibly leading
to an increased instability of the protein, as seen previously
for P0 wild-type protein when transgenically overexpressed
on a wild-type background (Wrabetz et al., 2000; Yin et al.,
2000). However, we consider this possibility as sole cause for
the impaired myelin development as unlikely. First, as men-
tioned above, the dysmyelinating phenotype in our mutants
is different from and less severe than that of the Tg80.2 mu-
tant studied by Wrabetz et al. (2000). Second, the frequent
profiles of dysmyelinated fibers in the biopsies from the
Ile106Leu patient are in line with the view that the mutation
not only causes tomacula formation, but also impairs myelin
formation as seen in the P0sub mice. Third, tomacula for-
mation occurs in both P0sub lines independently of the
amount of P0 protein expression in the myelin fraction.
This argues that not the levels of the combined mutant and
wild-type P0 proteins determine the characteristic features
of the resultant mouse lines, but that the tomacula seen in
the two independent founder P0sub-transgenic mice are the
true consequence of this mutation. Thus, our P0sub-trans-
genic mice represent an animal model of the severe tomacu-
lous form of the human mutation, as originally described by
Gabreëls-Festen et al. (1996).
The question of whether this mutation also leads to ab-
normal expression of other proteins involved in myelination,
such as PMP22, MAG, and periaxin, which produce tomac-
ula (Rebai et al., 1989; Adlkofer et al., 1995, 1997; Carenini
et al., 1997; Suter and Nave, 1999; Gillespie et al., 2000;
Boerkoel et al., 2001; Cai et al., 2001, 2002; Guilbot et al.,
2001; Takashima et al., 2002), remains presently unan-
swered. Tomacula are formed by homo- and heterozygous
deletions of the 
 
PMP22
 
 gene and the homozygous ablations
of the myelin-associated glycoprotein MAG and periaxin.
Because some of these molecules have been shown to inter-
act with each other, such as P0 with PMP22 (D’Urso et al.,
1999), and because dysregulations of a substantial set of my-
elin proteins in the peripheral nervous system of mutant
mice deficient in a particular myelin protein have been re-
peatedly observed (Martini and Schachner, 1997; Meni-
chella et al., 2001), it is possible that dysregulation in expres-
sion of the proteins so far recognized as causing tomacula
may indicate a common mechanism of molecular pathology.
The mechanism underlying the complex network of interde-
pendent synthesis, degradation, and subcellular localization
of the individual myelin proteins that may be affected by a
mutation in one gene will remain to be investigated to allow
a molecular interpretation of the abnormal phenotypes in
patients affected by P0 mutations. The availability of the
first mouse model carrying the human P0 mutation causing
tomacula is an important step toward elucidating these
mechanisms.
 
Materials and methods
 
Generation of P0sub-transgenic mice
 
To generate a mouse mutant expressing the pathogenic substitution P0
Ile106Leu (P0sub; Gabreëls-Festen et al., 1996; Fig. 1) under the control of
the P0 promoter (Feltri et al., 1999), the 2.6BsrGIsense vector, containing a
2.6-kb BsrGI fragment with exons 2–5 of the mouse P0 genomic DNA, was
used for mutagenesis. The adenine at bp 1644 (ATG start codon in the geno-
mic DNA as bp 1) was substituted to thymine using the Seamless PCR clon-
ing kit (Stratagene) according to the manufacturer’s protocol. In brief, the
whole vector was amplified with primers flanking and containing the muta-
tion and was re-ligated. A StuI–Eco47II fragment encoding exon 2 and mu-
tated exon 3 of the resulting 2.6BsrGIsense-P0sub vector was cloned into the
mP05.7blue vector (Lemke et al., 1988; Feltri et al., 1999), containing exons
2–6. Finally, an EcoRI fragment of the vector mP0Ewtblue (You et al., 1991;
Feltri et al., 1999) comprising the P0 promoter and exon 1 was inserted into
the EcoRI-digested mP05.7blue-P0sub vector.
The resulting transgenic constructs were verified by sequence analysis,
and 12.3-kb fragments were excised from the vectors using SpeI and XhoI.
The transgenes were microinjected into Friend virus B-type susceptibility
(FVB) zygotes using standard techniques (Hogan et al., 1994). Three P0sub
founder mice were identified by PCR and were crossed with wild-type FVB
mice. Breeding lines of two P0sub founders (called P0sub1 and P0sub3)
were crossed to FVB mice.
 
RT-PCR
 
Sciatic nerves were dissected from 6-wk-old P0sub1- and P0sub3-trans-
genic mice and from the respective wild-type littermates. Total RNA was
prepared using the RNeasy Lipid Tissue kit (QIAGEN) according to the
manufacturer’s instructions. To analyze transgene relative to endogenous
P0 expression, we used a modified version of the protocol described by
Feltri et al. (1999). For this purpose, we exploited the A
 
→
 
T point mutation
responsible for the Ile106Leu amino acid exchange. In brief, 200 ng total
RNA was reverse transcribed using Moloney Murine Leukemia Virus Re-
verse Transcriptase (Promega) and random hexanucleotide primers (Amer-
sham Biosciences). Equal volumes of the reverse-transcribed product from
sciatic nerves of transgenic and wild-type animals were amplified in the
presence of 
 
 
 
[
 
32
 
P]dATP, using a single primer pair recognizing P0 exon 2
(5 -GTCCAGTGAATGGGTCTCAG-3 ) and exon 4 (5 -GCTCCCAACAC-
CACCCCATA-3 ) that flanks a DdeI site present in the P0sub transgenes
only. PCR conditions were: initial enzyme activation at 95 C for 15 min;
followed by cycles consisting of 94 C for 30 s, 63 C for 60 s, and 72 C for
60 s; and a final extension step at 72 C for 10 min, in a standard PCR reac-
tion mix containing HotStarTaq DNA polymerase (QIAGEN). To avoid the
formation of heteroduplexes between the PCR products containing the ad-
ditional DdeI site and those lacking this site, only cycles in the logarithmic
range were chosen. Unincorporated nucleotides were removed from the
RT-PCR products using Micro Bio-Spin P-30 columns (Bio-Rad Laborato-
ries) according to the manufacturer’s instructions. 4  l of the purified RT-
PCR products was digested with DdeI (New England Biolabs) at 37 C for
90 min. DNA fragments were resolved by PAGE and visualized both by
phosphorimaging and by autoradiography. Intensity of the bands was
quantified by densitometry of phosphorimager signals (Fujix BAS 2000;
Fuji) using TINA 2.09 software (Raytest), and the ratio between the trans-
gene-specific 228-bp fragment and the endogene-specific 245-bp fragment
was calculated. To correct for the difference in incorporated dATPs, this
intensity ratio was multiplied by a correction factor (1.063), yielding the
transgenic P0 message/endogenous P0 message ratio.
Preparation of sciatic nerve homogenates and immunoblot analysis
The sciatic nerves of 2-mo-old wild-type and transgenic mice were ho-
mogenized in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1% NP-40, and 1  Complete
® protease inhibitor
cocktail [Roche]) and incubated at 4 C for 30 min. The homogenates were
cleared by centrifugation three times at 12,000 g at 4 C for 20 min. The
protein concentrations of homogenates were determined using the BCA
Protein Assay kit (Pierce Chemical Co.). The samples were denatured in
5  sample buffer (10% glycerol, 5%  -mercaptoethanol, 5% SDS, and
0.1% bromophenol blue) at 95 C for 5 min and subjected to SDS-PAGE
and immunoblot analysis using monoclonal (P07; 1:1,000 diluted; a gift of
Dr. Juan Archelos; Archelos et al., 1993) or polyclonal (1:750 diluted) P0
antibodies. Primary antibodies were detected with HRP-conjugated anti–
rat or anti–rabbit IgG (Dianova), and were visualized with ECL chemilumi-
nescent substrate (Amersham Biosciences). For the quantification of films
(BioMax; Kodak), images were captured by high resolution (600   600
dpi) 8-bit (256 gray level) microdensitometry with a flat-bed scanner (Ar-
cus II; Agfa). The images were analyzed for optical density of bands using
image analysis software (GelWorks 1D; Ultra-Violet Products). To deter-
mine the ratio between P0 expression in transgenic animals and P0 expres-
sion in wild-type animals, intensities of the main P0-immunoreactive band
(25 kD) were measured in lanes loaded with different amounts of total pro-
tein (see Fig. 3) and were normalized to the total protein amount.572 The Journal of Cell Biology | Volume 165, Number 4, 2004
Myelin preparation
8-wk-old mice (5 wild-type and 15 transgenic animals for each mouse
line) were anaesthetized using pentobarbital (Narcoren
®) and subsequently
perfused with PBS for 3–5 min in order to remove blood from peripheral
nerves. Sciatic nerves, femoral nerves, and dorsal roots were prepared and
frozen in liquid nitrogen. For homogenization, the nerves were mixed with
ice-cold homogenization buffer (5 mM Tris-HCl, pH 7.4, 1 mM NaHCO3,
and 320 mM sucrose) and homogenized in a Potter homogenizer. The ho-
mogenate was centrifuged at 100 g and 4 C for 10 min. After this centrifu-
gation step, the pellet and the supernatant were collected. The pellet was
resuspended in homogenization buffer, and supernatant and homogenized
pellet were applied on top of the first step sucrose gradient (320 mM – 650
mM – 1 M – 1.2 M). The gradients were centrifuged at 100,000 g and 4 C
for 1 h. The interface between the 320-mM and 650-mM sucrose solution
was collected, diluted with homogenization buffer, and centrifuged again
for 20 min at 100,000 g. The resulting pellets were osmotically shocked
and treated with 5 mM Tris-HCl, pH 8.3, for 45 min on ice. Afterwards, the
samples were centrifuged at 100,000 g and 4 C for 20 min. The pellets
were suspended in 5 mM Tris-HCl, pH 8.3, and applied to the top of a sec-
ond sucrose step gradient (0 mM – 650 mM – 850 mM – 1 M – 1.2 M). The
gradient was centrifuged at 100,000 g and 4 C for 1 h. The myelin fraction
was collected at the 0 – 650 mM sucrose interface, washed in ice-cold
PBS, and centrifuged for 30 min at 100,000 g. The resulting pellet was sus-
pended in PBS and frozen at  80 C. Protein content of the samples was
determined and immunoblot analyses were performed as described (see
above).
Preservation of tissue for light and electron microscopy
Femoral and sciatic nerves were processed for light and electron micros-
copy as reported earlier (Carenini et al., 2001). The mice were transcar-
dially perfused using 4% PFA and 2% glutaraldehyde in 0.1 M cacodylate
buffer (pH 7.4). The nerves stayed in the same fixative overnight, followed
by osmification and embedding in Spurr’s medium.
For light microscopic analysis, 0.5- m-thick semi-thin sections from
femoral nerves were stained with alkaline methylene blue and were inves-
tigated with a light microscope (Axiophot; Carl Zeiss MicroImaging, Inc.)
using a 40  objective. For EM, ultrathin sections of 70-nm thickness were
counterstained with lead citrate and investigated using an electron micro-
scope (model EM 10B; Carl Zeiss MicroImaging, Inc.). Primary magnifica-
tion was between 2,500 and 25,000.
Morphometry
The quantitative analysis of pathological changes was performed on ul-
trathin sections using a BioVision slow scan camera attached to the Zeiss
EM 10B microscope and using the corresponding software analySIS 3.0
Doku (Soft Imaging Systems). The following morphological parameters
were assessed: axons with myelin of normal thickness, axons with thin my-
elin, axons with folded myelin/tomacula, and myelin-competent axons
(larger than 1  m in diameter) devoid of myelin. For the determination of
relative myelin thickness, the g-ratio (a reciprocal measure of myelin thick-
ness; Friede, 1972), was determined as recently described (Kobsar et al.,
2003).
Statistical analysis
Comparison of the pathological features of the different genotypes was
done by use of a Mann-Whitney-U test and statistical significance was de-
fined for P   0.05. Statistical analysis of the data was performed by use of
Excel (Microsoft) and SYSTAT (SPSS, Inc.). Graphs were made using Sig-
maPlot 2001 (SPSS, Inc.).
Single-fiber preparations
Preparation of single nerve fibers was performed according to Martini et al.
(1995b). In brief, sciatic nerves of transcardially perfused mice (see earlier
in the Materials and methods) were removed and connective tissue around
the nerves was stripped off, followed by gentle “pre-teasing” of fiber bun-
dles. After osmification of fiber bundles and dehydration with acetone, sin-
gle-fiber preparation was performed in nonpolymerized Spurr’s medium
using no. 5 watchmaker’s forceps. Single fibers were transferred into a
droplet of Spurr’s medium on a slide, followed by cover-slipping and poly-
merization at 60 C. Light microscopy was performed with an Axiophot
light microscope (Carl Zeiss MicroImaging, Inc.) using a 40  objective.
Electrophysiological measurements
Nerve conduction experiments of sciatic nerves from 4- and 6-mo-old
mice were performed by established electrophysiological methods as de-
scribed previously (Zielasek et al., 1996). In brief, after anesthesia the com-
pound muscle action potential was recorded with two needle electrodes in
the foot muscles after distal stimulation of the tibial nerve, one main
branch of the sciatic nerve at the ankle, and proximal stimulation of the
sciatic nerve at the sciatic notch. In all experiments, the investigator was
not aware of the genotype. Statistical analysis was performed using a one-
tailed t test for grouped data.
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